arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

RECURSION PHARMACEUTICALS, INC.

RXRX
$3.21 ▲ +0.04 (+1.26%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

RECURSION PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B
Dividend Yield
Revenue Growth -56.1%
Op. Margin None
ROIC -12.1%
FCF / Share $-0.15
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.47M
↓ -56.1%
Net Income Profit after all expenses
$-117.50M
↑ +42.0%
Operating Margin Operating profit as % of sales
-304.8%
↑ +19.2%
FCF / Share Free cash flow per share
$-0.15
↑ +53.7%
Long-Term Debt Long-term obligations
$744.00K
↓ -94.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters